Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- Blocks CDK enzymes that let cells divide, to slow the growth of cancer cells.-ciclib: cyclin-dependent kinase inhibitors WHO name stem
- How it’s given
- “The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter”In the company’s words, NCT05394103 on ClinicalTrials.gov
- Tested for
- Advanced Cancer, Metastatic Cancer
- Main trialPhase 1/2
- “Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab”In the company’s words, NCT05394103 on ClinicalTrials.gov
Other drugs for Advanced Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- 31 Mar 2029Phase 1/2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 9 NovCompletion date moved: 2025-12-30 to 2029-03-31 · ClinicalTrials.gov NCT05394103
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 31 Mar 2029 | Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026